Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study - 15/04/25

Doi : 10.1016/j.jaad.2025.03.055

Won Ji Song, MD ^a,^b, Sohee Oh, PhD ^c, Hyun-Sun Yoon, MD, PhD ^b,^d,^⁎
^a Department of Dermatology, Seoul National University Hospital, Seoul, Korea
^b Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea
^c Medical Research Collaborating Center, SMG-SNU Boramae Medical Center, Seoul, Korea
^d Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea

^∗Correspondence to: Hyun-Sun Yoon, MD, PhD, Department of Dermatology, SMG-SNU Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul, Korea.Department of DermatologySMG-SNU Boramae Medical Center20 Boramae-ro 5-gilDongjak-guSeoulKorea

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Tuesday 15 April 2025
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Background

Limited data exist on managing psoriasis and psoriatic arthritis (PsA) in survivors of major adverse cardiovascular events (MACEs).

Objective

To investigate the risk of recurrent and new-onset MACEs associated with systemic therapies for psoriasis and PsA.

Methods

A retrospective cohort study using Korean health insurance data (January 2008-October 2021) included patients diagnosed with psoriasis or PsA treated with biologics, nonbiologic systemic therapy, or phototherapy. The primary outcome was MACE (acute myocardial infarction, stroke, cardiac arrest, unstable angina, or heart failure). Multivariable time-dependent Cox regression models were used for risk analysis.

Results

The study included 183,212 patients, yielding 259,475 treatment episodes. Biologic therapy was associated with a lower risk of new-onset and recurrent MACEs compared to phototherapy (adjusted hazard ratio, 0.454; 95% confidence interval [CI], 0.359-0.574; 0.343, 95% CI, 0.245-0.479, respectively). Nonbiologic systemic therapy showed a lower MACE risk than did phototherapy only in patients with a history of MACE (adjusted hazard ratio, 0.789; 95% CI, 0.658-0.946).

Limitations

Observational design limits causal inference and may involve residual confounding.

Conclusion

The study supports the use of biologics in patients with moderate-to-severe psoriasis or PsA, particularly those with a MACE history where treatment options are limited.

Le texte complet de cet article est disponible en PDF.

Key words : biologics, cardiovascular, cardiovascular disease, CVD, MACE, major adverse cardiovascular event, psoriasis, psoriatic arthritis, systemic

Abbreviations used : CI, CVD, HIRA, HR, IL, IQR, MACE, PsA, PY, SD, TNF-α

Plan

Introduction

Methods

Study design and patients

	Funding sources: The study was supported by the Dongwha Pharmaceutical Research Fund 2023, with no funder involvement in the study.
	Patient consent: Not applicable.
	IRB approval status: Exempted from IRB approval (IRB no. 07-2022-24).